Deleobuvir
CAS No. 863884-77-9
Deleobuvir ( BI 207127 | BI207127 | BI-207127 )
产品货号. M16258 CAS No. 863884-77-9
Deleobuvir (BI-207127, BI207127) 是一种有效的选择性 HCV NS5B 聚合酶抑制剂,针对 GT-1 HCV 聚合酶活性的 IC50 为 50 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥11097 | 有现货 |
|
50MG | ¥22518 | 有现货 |
|
100MG | ¥29970 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Deleobuvir
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Deleobuvir (BI-207127, BI207127) 是一种有效的选择性 HCV NS5B 聚合酶抑制剂,针对 GT-1 HCV 聚合酶活性的 IC50 为 50 nM。
-
产品描述Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients.HCV Infection Phase 3 Clinical.
-
体外实验——
-
体内实验——
-
同义词BI 207127 | BI207127 | BI-207127
-
通路Microbiology/Virology
-
靶点HCV
-
受体HCV
-
研究领域Infection
-
适应症HCV Infection
化学信息
-
CAS Number863884-77-9
-
分子量653.581
-
分子式C34H33BrN6O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(O)/C=C/C1=CC=C2N=C(C3(NC(C4=CC5=C(C=C4)C(C6CCCC6)=C(C7=NC=C(Br)C=N7)N5C)=O)CCC3)N(C)C2=C1
-
化学全称(E)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zeuzem S, et al. Gastroenterology. 2011 Dec;141(6):2047-55; quiz e14.
2. Zeuzem S, et al. Antivir Ther. 2013;18(8):1015-9.
3. Larrey D, et al. Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35.
4. LaPlante SR, et al. J Med Chem. 2014 Mar 13;57(5):1845-54.